









Markets
/
Stocks
/
nasdaq-cdt
/

Conduit Pharmaceuticals Inc

CDT

View Detailed Chart

5.670USD

+5.290+1392.11%

Market hours （ET）Quotes delayed by 15 min

7.85MMarket Cap

LossP/E TTM



Conduit Pharmaceuticals Inc

5.670

+5.290+1392.11%

Company

Intraday

30m

Today

+1392.11%

5 Days

+1285.63%

1 Month

+814.37%

6 Months

-38.44%

Year to Date

-17.35%

1 Year

-98.09%

View Detailed Chart

Agency Rating

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Buy

Sell(2)

Neutral(4)

Buy(6)

Indicators

Sell(1)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.022

Neutral

RSI(14)

32.752

Neutral

STOCH(KDJ)(9,3,3)

19.712

Neutral

ATR(14)

0.045

High Vlolatility

CCI(14)

-75.320

Neutral

Williams %R

82.309

Oversold

TRIX(12,20)

-2.434

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

0.403

Buy

MA10

0.435

Buy

MA20

0.499

Buy

MA50

0.729

Buy

MA100

2.513

Buy

MA200

7.360

Sell

News

More news coming soon, stay tuned...

Company

Conduit Pharmaceuticals, Inc. is a multi-asset clinical-stage, life science company. The Company facilitates the development and commercialization of clinical assets. The Company acquires and funds the development of Phase 2-ready assets, builds an integrated and advanced platform-driven approach powered by artificial intelligence (AI) and cybernetics, and seeks exit through third-party license deals following successful clinical trials. The Company’s asset pipeline includes AZD1656 (a Glucokinase Activator), AZD5658 (Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. It is used as a treatment option for Hashimoto’s Thyroiditis. AZD5904 includes a potent, irreversible inhibitor of human myeloperoxidase (MPO), for the treatment, prevention, and prophylaxis of idiopathic male infertility.

Company codeCDT

CompanyConduit Pharmaceuticals Inc

CEODr. Andrew Regan

Websitehttps://www.conduitpharma.com/